GlycoMimetics Inc (GLYC)
0.3158
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 11:13
GlycoMimetics Profit Margin (Quarterly)
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -90.79K% |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | -17.69K% |
| March 31, 2022 | |
| December 31, 2021 | -98.85K% |
| September 30, 2021 | -20.02K% |
| June 30, 2021 | -10.14M% |
| March 31, 2021 | -1.35K% |
| December 31, 2020 | -9.55K% |
| September 30, 2020 | -1.37K% |
| June 30, 2020 | |
| March 31, 2020 | -85.14% |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 |
| Date | Value |
|---|---|
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | -42.46K% |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | -25.11K% |
| September 30, 2015 | |
| June 30, 2015 | 51.85% |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | 53.18% |
| March 31, 2014 | |
| December 31, 2013 | -5.00K% |
| September 30, 2013 | -7.04K% |
| June 30, 2013 | -6.35K% |
| March 31, 2013 | 12.07% |
| December 31, 2012 | 16.41% |
| September 30, 2012 | 21.50% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-10.14M%
Minimum
Jun 2021
-85.14%
Maximum
Mar 2020
-1.15M%
Average
-17.69K%
Median
Jun 2022
Profit Margin (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 14.22% |
| Arbutus Biopharma Corp | -1.47K% |
| Revance Therapeutics Inc | -63.65% |
| FibroGen Inc | -36.87% |
| Cidara Therapeutics Inc | -- |